We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Romaana
Mir
romaana.mir@nhs.net
Tara
Chalk
tara.chalk@nhs.net
Mrs
Teresa
Young
teresa.young2@nhs.net
Melanoma and other malignant neoplasms of skin
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The European Organisation of Research and Treatment of Cancer’s Quality of Life Group (EORTC QLG) has developed a four-phase framework that can be used to develop and validate quality of life questionnaires for individuals with cancer. These are developed as modules to supplement their existing EORTC core quality of life questionnaire, the ‘QLQ-C30’. For example, modules have previously been developed for endometrial cancer (QLQEN24), bone metastases (QLQ-BM22), and cancer-related fatigue (QLQ-FA12). The four-phase approach comprises a literature review followed by interviews with patients and clinicians (Phase 1), construction of a questionnaire (Phase 2), refinement of the questionnaire (Phase 3), and finally administration of the questionnaire to an international sample in a full validation study (Phase 4).
The present study aims to contribute to the development of a module designed to measure quality of life in patients with Keratinocyte Carcinoma. The study aims to undertake Phase 1 of the above module development process.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
Patients with melanoma or cutaneous lymphoma. (i.e. any non Keritanomaous Carcinoma of the skin) Unable to speak English. (This is an international study and interviews will be conducted in other languages at other non UK sites.) Cognitive impairement such that patient cannot be interviewed.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Tara
Chalk
tara.chalk@nhs.net
Romaana
Mir
romaana.mir@nhs.net
Mrs
Teresa
Young
teresa.young2@nhs.net
The study is sponsored by EAST AND NORTH HERTFORDSHIRE NHS TRUST and funded by European Organisation for Research and Treatment of Cancer .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 57086
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
